MDR-END treatment study for multidrug-resistant TB
Part of Infections clinical trials.
This trial is studying a 9-month treatment plan for people with multidrug-resistant tuberculosis (MDR-TB) in South Korea. The goal is to see how well the MDR-END regimen works and how safe it is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years or older
- You have been diagnosed with multidrug-resistant tuberculosis (MDR-TB)
- Your TB bacteria are not resistant to fluoroquinolone antibiotics (like levofloxacin)
- You are not allergic to delamanid, linezolid, levofloxacin, or pyrazinamide
- You do not have a history of optic neuritis or peripheral neuritis
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study measures how TMC207 (an anti-TB medicine) works in the body and in combination with standard MDR-TB medicines for children and teens with lung MDR-TB. It may help clinicians learn the safest way to use TMC207 and how well it may support treatment.
This trial tests a personalized treatment approach for people with rifampicin-resistant TB that is still sensitive to fluoroquinolones. It aims to find the best combination of medicines based on your specific TB profile.
This trial tests whether using results from a detailed sputum (phlegm) test to tailor treatment improves outcomes in people with drug-resistant (rifampicin-resistant) pulmonary TB. It may help you get the most appropriate regimen based on your specific test results.
This trial tests a 6-month treatment for people with rifampicin-resistant tuberculosis (TB). It aims to see if a shorter, simpler regimen works as well as longer treatments. You may qualify if you have this type of TB and meet a few health requirements.
This trial tests a three-drug combination (bedaquiline, delamanid, and linezolid) to see if it's safe and works well for people with multi-drug resistant or rifampicin-resistant tuberculosis. It may offer a new treatment option if standard drugs aren't working.
This trial tests a new “triple-dose” set of medicines to treat people whose tuberculosis (TB) has come back in the lungs. If you qualify, the goal is to improve cure rates and reduce the chance of TB returning again.
Hear when a new Tuberculosis, Multidrug-Resistant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.